A multicomponent nanosystem for capturing circulating tumor cells from cancer patients with PD-L1 as an immunotherapy oncotarget†

IF 6.1 3区医学 Q1 MATERIALS SCIENCE, BIOMATERIALS Journal of Materials Chemistry B Pub Date : 2024-09-18 DOI:10.1039/D4TB01360C

Ganesh Khutale, Saloni Andhari, Rituja Gupta, Gourishankar Aland, Shashwat Banerjee, Kiran Todkar, Milind Pore, Vrushali Khobragade, Alain D’Souza, Narendra Kale, Aravindan Vasudevan, Atul Bharde, Sreeja Jayant, Yuvraj Patil and Jayant Khandare

{"title":"A multicomponent nanosystem for capturing circulating tumor cells from cancer patients with PD-L1 as an immunotherapy oncotarget†","authors":"Ganesh Khutale, Saloni Andhari, Rituja Gupta, Gourishankar Aland, Shashwat Banerjee, Kiran Todkar, Milind Pore, Vrushali Khobragade, Alain D’Souza, Narendra Kale, Aravindan Vasudevan, Atul Bharde, Sreeja Jayant, Yuvraj Patil and Jayant Khandare","doi":"10.1039/D4TB01360C","DOIUrl":null,"url":null,"abstract":"Capturing circulating tumor cells (CTCs) from the peripheral blood of cancer patients, where they are disseminated among billions of other blood cells, is one of the most daunting challenge. We report OncoDiscover®, a multicomponent nano-system consisting of iron oxide (Fe3O4) nanoparticles (NPs), polyamidoamine generation 4 dendrimers (PAMAM-G4-NH2), graphene oxide (GO) sheets and an anti-epithelial cell adhesion molecule (anti-EpCAM) antibody (Fe-GSH-PAMAM-GO-EpCAM) for the selective and precise capture of CTCs. We further evaluated this system for therapeutically important oncotargets, exemplifying overexpression of the programmed death ligand 1 (PD-L1) as a functional assay on CTCs in cancer patients. We retrospectively evaluated 134 cancer patients for the presence of CTCs and 113 (84%) showed the presence of CTCs. About 62 (55%) of the CTC +ve patients showed CTCs with PD-L1 expression. The personalized cancer detection demonstrated by the OncoDiscover® CTC analysis tool is highly relevant for cancer monitoring and treatment outcomes.","PeriodicalId":83,"journal":{"name":"Journal of Materials Chemistry B","volume":" 42","pages":" 10973-10982"},"PeriodicalIF":6.1000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Materials Chemistry B","FirstCategoryId":"1","ListUrlMain":"https://pubs.rsc.org/en/content/articlelanding/2024/tb/d4tb01360c","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Capturing circulating tumor cells (CTCs) from the peripheral blood of cancer patients, where they are disseminated among billions of other blood cells, is one of the most daunting challenge. We report OncoDiscover®, a multicomponent nano-system consisting of iron oxide (Fe₃O₄) nanoparticles (NPs), polyamidoamine generation 4 dendrimers (PAMAM-G4-NH₂), graphene oxide (GO) sheets and an anti-epithelial cell adhesion molecule (anti-EpCAM) antibody (Fe-GSH-PAMAM-GO-EpCAM) for the selective and precise capture of CTCs. We further evaluated this system for therapeutically important oncotargets, exemplifying overexpression of the programmed death ligand 1 (PD-L1) as a functional assay on CTCs in cancer patients. We retrospectively evaluated 134 cancer patients for the presence of CTCs and 113 (84%) showed the presence of CTCs. About 62 (55%) of the CTC +ve patients showed CTCs with PD-L1 expression. The personalized cancer detection demonstrated by the OncoDiscover® CTC analysis tool is highly relevant for cancer monitoring and treatment outcomes.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于捕获癌症患者循环肿瘤细胞的多组分纳米系统，以 PD-L1 作为免疫疗法的肿瘤靶点。

从癌症患者的外周血中捕获循环肿瘤细胞（CTC）是一项最艰巨的挑战，因为这些细胞散布在数十亿其他血细胞中。我们报告了 OncoDiscover®，这是一种多组分纳米系统，由氧化铁（Fe3O4）纳米颗粒（NPs）、聚酰胺胺第 4 代树枝状聚合物（PAMAM-G4-NH2）、氧化石墨烯（GO）薄片和抗上皮细胞粘附分子（anti-EpCAM）抗体（Fe-GSH-PAMAM-GO-EpCAM）组成，用于选择性地精确捕获 CTCs。我们进一步评估了这一系统对治疗重要肿瘤靶点的作用，例如将程序性死亡配体 1（PD-L1）的过度表达作为癌症患者 CTC 的功能检测指标。我们对 134 名癌症患者进行了 CTCs 存在情况的回顾性评估，结果显示 113 人（84%）存在 CTCs。约 62 例（55%）CTC +ve 患者的 CTC 具有 PD-L1 表达。OncoDiscover® CTC 分析工具所展示的个性化癌症检测与癌症监测和治疗效果密切相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Materials Chemistry B MATERIALS SCIENCE, BIOMATERIALS-

CiteScore

11.50

自引率

4.30%

发文量

866

期刊介绍： Journal of Materials Chemistry A, B & C cover high quality studies across all fields of materials chemistry. The journals focus on those theoretical or experimental studies that report new understanding, applications, properties and synthesis of materials. Journal of Materials Chemistry A, B & C are separated by the intended application of the material studied. Broadly, applications in energy and sustainability are of interest to Journal of Materials Chemistry A, applications in biology and medicine are of interest to Journal of Materials Chemistry B, and applications in optical, magnetic and electronic devices are of interest to Journal of Materials Chemistry C.Journal of Materials Chemistry B is a Transformative Journal and Plan S compliant. Example topic areas within the scope of Journal of Materials Chemistry B are listed below. This list is neither exhaustive nor exclusive： Antifouling coatings Biocompatible materials Bioelectronics Bioimaging Biomimetics Biomineralisation Bionics Biosensors Diagnostics Drug delivery Gene delivery Immunobiology Nanomedicine Regenerative medicine & Tissue engineering Scaffolds Soft robotics Stem cells Therapeutic devices

期刊最新文献

Back cover Back cover Back cover Expression of concern: Surface modification engineering of two-dimensional titanium carbide for efficient synergistic multitherapy of breast cancer Reconfiguring the endogenous electric field of a wound through a conductive hydrogel for effective exudate management to enhance skin wound healing†